In 2017, a biohacker named Josiah Zayner livestreamed injecting himself with a DIY CRISPR kit targeting the myostatin gene — theoretically to increase muscle mass. In 2018, a doctor named Liz Parrish claimed to have given herself gene therapy for muscle wasting and telomere extension at a clinic in Colombia. In 2019, a scientist named He Jiankui was sentenced to prison in China for editing the genomes of human embryos that were subsequently born as babies. The arc of genetic self-experimentation runs from the startling to the criminal, and the science underpinning all of it — CRISPR-Cas9 gene editing — is simultaneously one of the greatest scientific achievements of the 21st century and one of the most dangerous tools to put in untrained hands.
What CRISPR-Cas9 Actually Is
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a bacterial immune defense system adapted for use as a gene-editing tool. In nature, bacteria use CRISPR sequences to remember viral DNA sequences and the Cas9 protein as a molecular scissors that cuts matching sequences when the virus attacks again.
In the laboratory, researchers have adapted this system to cut DNA at virtually any target sequence of their choosing. By providing a guide RNA that matches the target sequence and the Cas9 protein, researchers can cut genomic DNA at a specific location. The cell then repairs the cut — either imprecisely (knocking out gene function) or, if a template is provided, incorporating a specific edit into the sequence. This capability, which took researchers decades to approximate with earlier gene-editing technologies, can now be set up in a basic molecular biology laboratory in a matter of days.
Key fact: The 2020 Nobel Prize in Chemistry was awarded to Jennifer Doudna and Emmanuelle Charpentier for developing CRISPR-Cas9 as a gene editing tool — recognition of how fundamentally it transformed the biological sciences.
The DIY Biohacking Reality: What People Are Actually Doing
DIY bio communities have proliferated since the early 2010s, with community laboratories in major cities and online marketplaces selling CRISPR kits for bacterial and yeast editing (these are legal educational products). The educational kits — used to modify bacterial resistance genes or make yeast glow — are largely harmless and have genuine educational value.
The much smaller subset of individuals who have attempted human CRISPR self-experimentation is on a different level of risk entirely. Josiah Zayner, perhaps the most prominent, has himself expressed regret about having livestreamed self-experiments that he believes inspired others to attempt similar things less carefully. The challenges of human self-CRISPR are qualitatively different from laboratory experiments:
- Delivery of CRISPR components into human tissue at scale is an unsolved problem even for well-funded pharmaceutical companies. Viral vectors (typically AAV) are the leading delivery method but carry significant immune reaction risks.
- Off-target edits — cuts at unintended genomic locations — occur at low but nonzero rates. In somatic cells, this raises cancer risk if a tumor suppressor or oncogene is inadvertently disrupted.
- In germline cells (sperm, eggs, or embryos), edits are heritable and permanent — affecting all descendants, who have no opportunity to consent.
- Quality control in self-assembled CRISPR formulations is essentially nonexistent.
Legal and Regulatory Status: A Global Patchwork
The regulatory status of human genetic modification varies significantly by country, but is broadly restrictive for somatic (non-heritable) gene therapy and nearly universally prohibited for germline (heritable) editing of human embryos intended for implantation. In the United States, somatic gene therapy is regulated as a biologic drug by the FDA — any administration to humans requires an IND application. Self-administration of unapproved gene therapy may violate FDA regulations, though prosecutions targeting individuals rather than companies have been rare.
He Jiankui’s imprisonment was under Chinese law governing illegal medical practice, not specifically a gene-editing statute — reflecting how the legal frameworks struggle to keep pace with technical capabilities. Several countries (Germany, Canada, Australia) have explicit laws criminalizing human germline modification. Others have no specific statute but would likely prosecute under existing medical practice or criminal harm laws.
What Legitimate Gene Therapy Actually Looks Like
The contrast between DIY CRISPR and legitimate gene therapy is instructive. As of 2026, the FDA has approved several gene therapies — including Casgevy (betibeglogene autotemcel), the first approved CRISPR-based therapy, for sickle cell disease and beta-thalassemia. These approvals required years of preclinical safety studies, careful off-target analysis, Phase I/II/III human trials in hundreds of patients, and manufacturing processes that ensure consistent, characterized product.
The pathway from CRISPR target identification to safe human therapy has taken, in the fastest cases, about a decade and cost hundreds of millions of dollars. That investment exists precisely because the consequences of getting it wrong — unexpected immune reactions, off-target oncogenic mutations, heritable germline errors — are severe and potentially irreversible.
The Longevity Angle: Why This Is Relevant to Aging Science
The longevity community’s interest in genetic modification centers on theoretically high-value targets: telomere extension, myostatin inhibition, APOE4 modification, FOXO3 upregulation, and others. Some of these have genuine scientific rationale. But the path from “this gene variant is associated with longevity in population studies” to “editing this gene in an adult human will extend your lifespan” involves assumptions about causality, tissue-specificity, off-target effects, and systemic consequences that cannot currently be resolved with DIY methods.
The honest verdict: DIY CRISPR self-experimentation for longevity is not a frontier of citizen science — it is a category of risk that reflects the human tendency to apply incomplete tools to incompletely understood systems with permanent consequences. The legitimate path runs through institutional research, regulatory frameworks, and the hard work of building an actual evidence base.
At lifespan.asia, we follow the gene therapy pipeline — from approved CRISPR therapies for genetic disease to longevity-relevant targets in legitimate clinical development. The genetics of aging is genuinely fascinating and increasingly tractable. The DIY shortcut bypasses everything that makes the science trustworthy. Follow our coverage for an honest account of where the field is actually headed.